quinazolines has been researched along with Agnogenic Myeloid Metaplasia in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Bieniaszewska, M; Dutka, M; Leszczyńska, A; Sobieralski, P | 1 |
| Begna, KH; Christopher Hook, C; Elliott, MA; Gangat, N; Hanson, CA; Ketterling, RP; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vallapureddy, RR; Wolanskyj, AP | 1 |
| Alvarez-Larrán, A; Besses, C; Cervantes, F | 1 |
| Fu, R; Yang, R; Zhang, L | 1 |
| Ballester-Sánchez, R; de Unamuno-Bustos, B; Sabater Marco, V; Vilata-Corell, JJ | 1 |
| Miyamoto, T; Yoshimoto, G | 1 |
| Alvarez, C; Ferrari, L; Glembotsky, AC; Goette, NP; Gutierrez, MI; Heller, PG; Korin, L; Lev, PR; Maldonado, AC; Marta, RF; Mela Osorio, MJ; Molinas, FC | 1 |
| Bareford, D; Buck, G; Campbell, PJ; Erber, WN; Green, AR; Harrison, CN; Wheatley, K; Wilkins, BS; Wright, P | 1 |
| Dai, Y; Hoffman, R; Ishii, T; Mascarenhas, J; Najfeld, V; Sozer, S; Wang, J; Wisch, N; Xu, M; Zhang, W; Zhao, ZJ | 1 |
| Beer, PA; Green, AR | 1 |
| Buliková, A; Doubek, M; Dulícek, P; Hlusí, A; Kissová, J; Korístek, Z; Ovesná, P; Pavlík, T; Penka, M; Pospísilová, D; Schwarz, J | 1 |
| Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE | 1 |
| Barbui, T; Finazzi, G | 1 |
| Silver, R | 1 |
| Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J | 1 |
| Liu, D; Seiter, K; Yalamanchili, K | 1 |
| Birgegård, G; Engström-Laurent, A; Hultdin, M; Lundström, B; Samuelsson, J; Sundström, G; Wahlin, A | 1 |
| Bennett, M; Chubar, E | 1 |
| Cervantes, F | 2 |
| Bareford, D; Buck, G; Campbell, PJ; East, CL; Erber, WN; Green, AR; Harrison, CN; Paul, B; Wheatley, K; Wilkins, BS | 1 |
| Sréter, L | 1 |
| Li, CY; Mesa, RA; Tefferi, A; Yoon, SY | 1 |
| Silverstein, MN; Tefferi, A | 1 |
7 review(s) available for quinazolines and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; GPI-Linked Proteins; Hemorrhage; Humans; Hydroxyurea; Incidence; Infant; Isoantigens; Janus Kinase 2; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Point Mutation; Primary Myelofibrosis; Quinazolines; Receptors, Cell Surface; Risk Assessment; Symptom Assessment; Thrombocythemia, Essential; Thrombophilia | 2013 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential | 2014 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia | 2009 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide | 2007 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis | 1998 |
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Combined Modality Therapy; Female; Hemoglobins; Humans; Hydroxyurea; Karyotyping; Male; Middle Aged; Palliative Care; Primary Myelofibrosis; Prognosis; Quinazolines; Risk; Severity of Illness Index; Splenectomy; Survival Analysis; Thalidomide | 2001 |
4 trial(s) available for quinazolines and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombosis | 2009 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2005 |
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Fibrinolytic Agents; Humans; Hyaluronic Acid; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombocytosis | 2007 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematology; Humans; Hydroxyurea; Megakaryocytes; Observer Variation; Pathology, Clinical; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocytosis | 2008 |
13 other study(ies) available for quinazolines and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population.
Topics: Child; Erythropoietin; Humans; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 2022 |
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow; Disease Progression; Disease-Free Survival; Drug Approval; Female; Fibrosis; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult | 2019 |
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; Humans; Hydroxyurea; Leg Ulcer; Lichenoid Eruptions; Precancerous Conditions; Primary Myelofibrosis; Quinazolines | 2014 |
Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Calreticulin; Child; Female; Follow-Up Studies; Gene Expression; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential | 2016 |
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Topics: Antigens, CD34; Cells, Cultured; Erlotinib Hydrochloride; Humans; Janus Kinase 2; Mast Cells; Mutation; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2009 |
[Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 2010 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 2005 |
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
Effects of anagrelide on megakaryopoiesis and platelet production.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Humans; Hydroxyurea; Megakaryocytes; Mutagenesis; Platelet Aggregation Inhibitors; Ploidies; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombopoiesis; World Health Organization | 2006 |
Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
Topics: Antigens, CD; Benzamides; Bone Marrow Cells; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 3; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Remission Induction; Splenomegaly; Translocation, Genetic | 2007 |
Chronic myeloid leukemia evolving after idiopathic myelofibrosis.
Topics: Adult; Blood Cell Count; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Megakaryocytes; Primary Myelofibrosis; Quinazolines; Splenomegaly; Thrombocytopenia; Translocation, Genetic | 2007 |
[Chronic myeloproliferative diseases].
Topics: Chronic Disease; Female; Fibrinolytic Agents; Humans; Interferons; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 1998 |
Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.
Topics: Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Prospective Studies; Quinazolines | 1999 |